Applications

1407 – EGFR mutation testing to determine eligibility for access to PBS subsidised AZD9291 second line therapy in patients with locally advanced or metastatic NSCLC

Find out about the service or technology in this application and the medical condition it addresses. You can also view the application documents, the deadlines for providing consultation input and the outcome of the application when the MSAC process is complete.

  • Status Complete
  • Type New application
  • Pre-PASC consultation -
  • Pre-MSAC consultation -
  • Outcome Supported

Application details

Reason for application

Amendment to MBS item.

Service or technology in this application

The proposed medical service is an additional EGFR mutation test for the presence of the T790M mutation in patients with locally advanced (Stage IIIB) or metastatic (Stage IV), non-squamous or not otherwise specified EGFR mutation positive NSCLC, who have received first-line EGFR TKI treatment and whose disease has subsequently progressed.

Type: Co-dependent technology

Medical condition this application addresses

Lung cancer is the fourth most commonly diagnosed cancer in Australian men and women(1). Unfortunately, approximately 50% of patients with lung cancer are diagnosed when the disease is advanced and inoperable (2). Prognosis is poor with a 5-year survival rate of approximately 13% (3). In the past decade, targeted therapies for treatment of specific molecular subtypes of lung cancer have become available. There are approved and established therapies for patients with non-small cell lung cancer (NSCLC) known to have sensitising mutations of the Epidermal Growth Factor Receptor (EGFR) gene. Treatment with EGFR tyrosine kinase inhibitors (TKIs) is not curative and the disease will ultimately progress in the majority of patients within 9-13 months (4).

Meetings to consider this application

  • PASC meeting: 13 - 14 August 2015
  • ESC meeting: 5 October 2017
  • MSAC meeting: 
    • 23 November 2017
    • 22 - 23 November 2018